Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976431 | 0.92 | MAPT (0.38) | MAPTALDH1A1NPY2RTAS2R8LMNA | |
| SCHEMBL2978680 | 0.89 | NPY2R (0.39) | NPY2R | |
| SCHEMBL2981578 | 0.83 | NPY2R (0.44) | MAPTNPY2RFPR2TAS2R8LMNA | |
| SCHEMBL3657660 | 0.81 | RAB9A (0.40) | MEN1KMT2AMAPTCASP3TRPV1 | |
| SCHEMBL2976845 | 0.79 | MAPT (0.41) | MAPTALDH1A1NPY2RTAS2R8LMNA | |
| SCHEMBL2984019 | 0.78 | RXFP1 (0.36) | — | |
| SCHEMBL2984550 | 0.77 | P2RX7 (0.42) | NPY2R | |
| SCHEMBL3664126 | 0.72 | KMT2A (0.52) | MEN1KMT2AMAPTALDH1A1FPR2 | |
| SCHEMBL3659849 | 0.72 | TSHR (0.49) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2986110 | 0.71 | KCNH2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786155-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | claimed |
| US-7786155-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | disclosed |
| EP-2212295-A2 | 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050201-A2 | 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099244-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099244-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLC10A6, SLCO1B1 | MEN1 235/4885KMT2A 1654/4885MAPT 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.